These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23047788)

  • 61. The Value of the Black Box Warning in Dermatology.
    Winterfield L; Vleugels RA; Park KK
    J Drugs Dermatol; 2015 Jul; 14(7):660-6. PubMed ID: 26151780
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prescribing Antipsychotic Medications to Patients With Dementia: Boxed Warnings and Mitigation of Legal Liability.
    Rose RV; Kass JS
    Continuum (Minneap Minn); 2019 Feb; 25(1):254-259. PubMed ID: 30707196
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Boxed Warning for Montelukast: The FDA Perspective.
    Clarridge K; Chin S; Eworuke E; Seymour S
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2638-2641. PubMed ID: 33744471
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Tactics of management of preschool children with different variants of speech delay].
    Lar'kina EV; Khaletskaia OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(12):94-98. PubMed ID: 25726787
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A 12-week nursing support programme for carers of children and adolescents in the UK with attention deficit hyperactivity disorder prescribed atomoxetine.
    Savill N; Pelton J; Lenox-Smith A; Bushe CJ
    Ther Adv Psychopharmacol; 2013 Apr; 3(2):65-71. PubMed ID: 24167677
    [TBL] [Abstract][Full Text] [Related]  

  • 66. FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomes.
    Rosenberg M; Sheehan S; Zhou E; Pinnow E; Burnell J; Romine M; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1022-1029. PubMed ID: 32790031
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Conflicting information from TGA versus FDA may undermine compliance with use of medication.
    Beckmann KM
    Med J Aust; 2013 Jul; 199(1):28-9. PubMed ID: 23829255
    [No Abstract]   [Full Text] [Related]  

  • 68. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights July-September 2016.
    Rubio T
    Hosp Pharm; 2016 Dec; 51(11):941-943. PubMed ID: 28057955
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Summaries of Safety Labeling Changes Approved By FDA—Boxed Warnings Highlights January-March 2015.
    Rubio T
    Am J Health Syst Pharm; 2015 Jun; 72(11):900, 902, 904. PubMed ID: 25987678
    [No Abstract]   [Full Text] [Related]  

  • 70. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights October - December 2016.
    Rose BJ
    Hosp Pharm; 2017 Feb; 52(2):153-154. PubMed ID: 28321144
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Children's exposure to testosterone gel spurs FDA to order boxed label warning.
    Voelker R
    JAMA; 2009 Jun; 301(23):2428. PubMed ID: 19531774
    [No Abstract]   [Full Text] [Related]  

  • 72. The FDA Revises Boxed Warning For Fluoroquinolones-Again.
    Aschenbrenner DS
    Am J Nurs; 2016 Sep; 116(9):22-3. PubMed ID: 27560334
    [No Abstract]   [Full Text] [Related]  

  • 73. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
    Bablani S; Janodia MD
    Ther Innov Regul Sci; 2020 Jul; 54(4):925-931. PubMed ID: 32557315
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacogenomic testing and antithrombotic therapy: ready for prime time?
    Holmes DR
    Rambam Maimonides Med J; 2013 Jan; 4(1):e0005. PubMed ID: 23908855
    [TBL] [Abstract][Full Text] [Related]  

  • 75. FDA clearance paves way for computerized ADHD monitoring.
    Dolgin E
    Nat Med; 2014 May; 20(5):454-5. PubMed ID: 24804740
    [No Abstract]   [Full Text] [Related]  

  • 76. Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice.
    Esterly JS; Steadman E; Scheetz MH
    Int J Clin Pharm; 2011 Jun; 33(3):537-42. PubMed ID: 21544560
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synthetic food colors and neurobehavioral hazards: the view from environmental health research.
    Weiss B
    Environ Health Perspect; 2012 Jan; 120(1):1-5. PubMed ID: 21926033
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Strattera: ups, downs, and emerging uses.
    Cascade EF; Kalali AH; Feifel D
    Psychiatry (Edgmont); 2007 Apr; 4(4):23-5. PubMed ID: 20711324
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Public Perceptions of Breast Implant Complications and the FDA Boxed Warning on Implants.
    Hyland CJ; Gadiraju G; Parikh N; Dey T; Broyles JM
    Plast Reconstr Surg Glob Open; 2022 Nov; 10(11):e4439. PubMed ID: 36381489
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Suicidality as a Possible Side Effect of Antidepressant Treatment.
    Culpepper L; Davidson JR; Dietrich AJ; Goodman WK; Kroenke K; Schwenk TL
    Prim Care Companion J Clin Psychiatry; 2004; 6(2):79-86. PubMed ID: 15254601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.